Could a simple blood injection revive aging ovaries?

NCT ID NCT04278313

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether injecting a woman's own platelet-rich plasma (PRP) into her ovaries can improve egg quality and IVF success. About 90 women with low ovarian reserve (due to age or other causes) will receive either PRP or a placebo injection. The main goal is to see if more usable embryos can be produced for fertility treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 44 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * fewer than 6 oocytes in response to past ovulation induction * desire to establish a pregnancy using IVF * Age 44 years and under. * FSH \> 12 * AMH \< 1.0 * No Aspirin or Motrin for one week before treatment Exclusion Criteria: * Age \> 45 years * Marked thrombocytopenia * Blood diseases * Hypofibrinogenemia * Hemodynamic instability * Anticoagulant or antiaggregant treatment * Oncological diseases (specially, skeletal system and blood) * Sepsis * Acute and chronic infectious diseases * Autoimmune diseases, for example, lupus erythematosus, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diminished ovarian reserve are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center for Human Reproduction

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.